Skip to main content
OpenTrials

Clinical trial condition

Lymphoma, Large B-Cell, Diffuse

Explore clinical trials studying Lymphoma, Large B-Cell, Diffuse. Study availability and eligibility vary by location and protocol.

1,249 public trials 217 recruiting studies
Refine in advanced search Browse all conditions

Lymphoma, Large B-Cell, Diffuse trial results

Recruiting

A Clinical Study of MK-1045 in People With Non-Hodgkin Lymphoma (MK-1045-008)

NCT07519772

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +9 more
Locations
  • Colorado Blood Cancer Institute ( Site 7000) Denver, Colorado, United States
  • SCRI Oncology Partners ( Site 0100) Nashville, Tennessee, United States
  • Instituto Alexander Fleming ( Site 1404) Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina
  • Sanatorio Nuestra Senora del Rosario ( Site 1403) Rosario, Santa Fe Province, Argentina
View all 22 locations
View Trial Details
Recruiting

Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)

NCT06395103

Conditions
B-cell Acute Lymphoblastic Leukemia, Burkitt Lymphoma, DNA Virus Infections, +32 more
Locations
  • Children's Hospital Los Angeles ( Site 1006) Los Angeles, California, United States
  • Children's Hospital Colorado-Center for Cancer and Blood Disorders ( Site 1016) Aurora, Colorado, United States
  • Yale New Haven Hospital ( Site 1012) New Haven, Connecticut, United States
  • Johns Hopkins All Children's Hospital ( Site 1025) St. Petersburg, Florida, United States
View all 71 locations
View Trial Details
Recruiting

The CARDIOPROTECT Trial

NCT07654426

Conditions
Cardiotoxicity, Cardiovascular Diseases, Chemically-Induced Disorders, +18 more
Locations
  • Beth Israel Deaconess Medical Center Boston, Massachusetts, United States
View Trial Details
Recruiting

A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies

NCT05006716

Conditions
B-cell Malignancy, Blood Protein Disorders, Cardiovascular Diseases, +37 more
Locations
  • University of Alabama At Birmingham Hospital Birmingham, Alabama, United States
  • Mayo Clinic Phoenix Phoenix, Arizona, United States
  • Honor Health Research Institute Scottsdale, Arizona, United States
  • University of Arizona Cancer Center Tucson, Arizona, United States
View all 127 locations
View Trial Details
Recruiting

A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Adult Patients With Previously Untreated Diffuse Large B-cell Lymphoma

NCT06091865

Conditions
Diffuse Large B-Cell Lymphoma (DLBCL), Hemic and Lymphatic Diseases, Immune System Diseases, +9 more
Locations
  • Mayo Clinic - Arizona Scottsdale, Arizona, United States
  • David Geffen School of Medicine at UCLA Los Angeles, California, United States
  • University of California Irvine Medical Center Orange, California, United States
  • University of California (UC) Davis Sacramento, California, United States
View all 168 locations
View Trial Details
Recruiting

A Study of Glofitamab-based Treatment in People With Diffuse Large B-cell Lymphoma

NCT06765317

Conditions
Diffuse Large B Cell Lymphoma (DLBCL), Hemic and Lymphatic Diseases, High Grade B Cell Lymphoma, +10 more
Locations
  • Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities) Basking Ridge, New Jersey, United States
  • Hackensack Meridian Health (Data collection only) Hackensack, New Jersey, United States
  • Memorial Sloan Kettering Monmouth (Limited Protocol Activities) Middletown, New Jersey, United States
  • Memorial Sloan Kettering Bergen (Limited Protocol Activities) Montvale, New Jersey, United States
View Trial Details
Recruiting

A Phase III Study of HMPL-760 Plus R-GemOx VS Placebo Plus R-GemOx in Relapsed/Refractory DLBCL

NCT07409428

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +9 more
Locations
  • Fudan University Shanghai Cancer Center Shanghai, Shanghai Municipality, China
  • Baoding NO.1 Central Hospital Baoding, China
  • Beijing GoBroad Hospital Beijing, China
  • BEIJING TONGREN HOSPITAL, Capital Medical University Beijing, China
View all 50 locations
View Trial Details
Recruiting

A Study to Evaluate the Optimization of the Cytokine Release Syndrome Profile for Glofitamab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed/Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma

NCT06806033

Conditions
B-Cell Non-Hodgkins Lymphoma, Cytokine Release Syndrome, Disease Attributes, +17 more
Locations
  • Alaska Oncology & Hematology, LLC Anchorage, Alaska, United States
  • Community Cancer Institute (CCI) Clovis, California, United States
  • Providence Medical Foundation Fullerton, California, United States
  • Los Angeles Cancer Network Glendale, California, United States
View all 53 locations
View Trial Details

Related conditions